

# Asparlas<sup>®</sup> (calaspargase pegol-mknl) and Oncaspar<sup>®</sup> (pegaspargase)

## Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

### Drug Information

☐ Physician billing (HCPCS code: \_\_\_\_\_) ☐ Pharmacy billing (NDC: \_\_\_\_\_)

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_ Start Date (or date of next dose): \_\_\_\_\_

### Billing Provider Information

Provider NPI: \_\_\_\_\_ Provider Name: \_\_\_\_\_

Provider Phone: \_\_\_\_\_ Provider Fax: \_\_\_\_\_

### Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

### Criteria

#### For Initial Authorization:

##### 1. Please indicate the diagnosis and information:

##### ☐ Acute Lymphoblastic Leukemia (ALL)

A. Will the treatment be used as a component of multi-agent chemotherapy? Yes ☐ No ☐

B. For Asparlas<sup>®</sup> (calaspargase pegol-mknl), please provide a patient-specific, clinically significant reason why the member cannot use Oncaspar<sup>®</sup> (pegaspargase): \_\_\_\_\_

##### ☐ Extranodal NK/T-Cell Lymphoma

A. Does member have nasal or extranasal disease? Yes ☐ No ☐

i. If yes, will this be used as induction therapy? Yes ☐ No ☐

ii. If yes, will this be used as additional therapy in members with a positive biopsy following a partial response or no response to induction therapy? Yes ☐ No ☐

B. For Asparlas<sup>®</sup> (calaspargase pegol-mknl), please provide a patient-specific, clinically significant reason why the member cannot use Oncaspar<sup>®</sup> (pegaspargase): \_\_\_\_\_

☐ If answer is none of the above, please indicate diagnosis: \_\_\_\_\_

Additional Information: \_\_\_\_\_

#### For Continued Authorization:

1. Date of last dose: \_\_\_\_\_

2. Does member have any evidence of progressive disease while on Asparlas<sup>®</sup> or Oncaspar<sup>®</sup>? Yes ☐ No ☐

3. Has the member experienced adverse drug reactions related to Asparlas<sup>®</sup> or Oncaspar<sup>®</sup> therapy? Yes ☐ No ☐

If yes, please specify adverse reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

#### CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds<sup>®</sup> or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.